loading page

The Use of Cannabis Derived Medical Products in the Treatment of Children’s Cancer: A Systematic Review
  • +2
  • Nikolai Gajic,
  • Cait Murphy,
  • Sarah Ritchie,
  • Charlie Saunders,
  • Dermot Murphy
Nikolai Gajic
University of Glasgow School of Veterinary Medicine
Author Profile
Cait Murphy
University of St Andrews School of Medicine
Author Profile
Sarah Ritchie
University of St Andrews School of Medicine
Author Profile
Charlie Saunders
University of Glasgow School of Veterinary Medicine
Author Profile
Dermot Murphy
NHS Greater Glasgow and Clyde North Glasgow Biochemistry
Author Profile

Abstract

Legislative change to cannabis use has generated significant interest into the therapeutic utility of cannabis-derived medical products, particularly in the field of oncology. However, much of this research has focused on adults, leaving physicians and caregivers uncertain as to the safety and efficacy of cannabinoids amongst the pediatric demographic. To this end, the aim of this review is to examine the scope of pharmaceutical cannabis in treatment of pediatric cancer, evaluating its utility as an anti-cancer therapeutic as well as symptom relief agent. This systematic review was conducted following the PRISMA guidelines. 30 included articles comprised of 16 clinical and 14 preclinical studies. There is reasonable evidence to support the use of cannabis in CINV, with plausible utility for other facets of symptomatic relief. Preclinical pediatric cancer models, investigating anti-cancer cannabinoid effect, have provided evidence that may warrant first phase clinical trials.
20 Sep 2022Assigned to Editor
20 Sep 2022Submission Checks Completed
20 Sep 2022Submitted to Pediatric Blood & Cancer
22 Sep 2022Reviewer(s) Assigned